Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151502 | 0.86 | MGAM (0.47) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL5151414 | 0.83 | ACHE (0.56) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL5156362 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL5152300 | 0.78 | HCRTR1 (0.56) | ALDH1A1MGAMTSHRSMN1; SMN2KDM4E | |
| SCHEMBL5156712 | 0.78 | GAA (0.60) | ALDH1A1TSHRSMN1; SMN2KDM4EGAA | |
| SCHEMBL5149502 | 0.77 | MGAM (0.56) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL5151382 | 0.76 | ALDH1A1 (0.54) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL5155489 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL7123666 | 0.74 | MGAM (0.56) | ALDH1A1MGAMTSHRHPGDSMN1; SMN2 | |
| SCHEMBL5152128 | 0.74 | ALDH1A1 (0.48) | ALDH1A1MGAMSMN1; SMN2KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113421-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders | TRPV2, RYR2, VDAC2 | ALDH1A1 3381/4885MGAM 2524/4885TSHR 2154/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | ALDH1A1 1370/4885MGAM 3677/4885TSHR 3944/4885 |
| US-20050148587-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | ALDH1A1 1370/4885MGAM 3677/4885TSHR 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.